Monday, March 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

AvidBiotics Granted Patent for Novel Immunotherapeutic Platform

by Global Biodefense Staff
April 1, 2014

AvidBiotics Corp., a developer of novel non-antibody proteins targeting bacteria, cancer, and virus-infected cells, this week announced that it has received an issued patent from the U.S. Patent and Trademark Office covering the targetable immunotherapeutic platform being developed by the company.

The patent is entitled “Non-Natural MIC Proteins,” and claims bi-specific, engineered human MIC proteins, termed Micacide™ proteins by the company, that simultaneously bind to selected cell surface targets and to the NKG2D activating receptor expressed on natural killer (NK) cells and certain T cells. 

Micacide proteins act as adapters between the targeted cells (e.g., cancer or virus-infected cells) and cells of the innate immunity system to direct killing of the targeted cells. AvidBiotics is leveraging this platform technology to develop first-in-class immunotherapeutics capable of directing an immune response through the NKG2D receptor pathway toward a number of specific cancers and viral targets.

The innate immunity system plays an important role in fighting cancer and viral infection by maintaining constant surveillance against cells that express surface MIC proteins, the presence of which indicates that the cells are a threat. Once NK cells, for example, detect a cell decorated with MIC protein, they attack and destroy the cell. However, many cancerous or infected cells do not express a level of MIC protein sufficient to recruit the cells of the innate immunity system, or the harmful cells evade detection by shedding their MIC surface markers.

“The Micacide proteins encompassed by this patent are designed to overcome the escape of these malignant or infected cells from NK and T cell surveillance,” said David W. Martin, M.D., AvidBiotics Chief Executive Officer. “These proteins therefore provide a potentially powerful mechanism for harnessing our own innate immunity systems to fight cancer and viral infections.”

Related Posts

small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development
Industry News

DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development

January 10, 2023
Bavarian Nordic to Supply Additional Monkeypox Vaccine to EU Member States
Industry News

Bavarian Nordic to Supply Additional Monkeypox Vaccine to EU Member States

September 7, 2022
Arcturus Awarded $63.2M to Advance Self-amplifying mRNA Vaccine for Pandemic Influenza Response
Industry News

Arcturus Awarded $63.2M to Advance Self-amplifying mRNA Vaccine for Pandemic Influenza Response

August 31, 2022
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC